Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study

Multiple Myeloma (MM)

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Eur J Cancer

Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B

doi: 10.1016/j.ejca.2024.115157

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

Skin Cancer

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Eur J Cancer

Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S

doi: 10.1016/j.ejca.2024.115099

Leukemia

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Leukemia

Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Gao S, Rane D, Guo S

doi: 10.1038/s41375-025-02608-4

Breast Cancer

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

J Natl Cancer Inst

Bargon CA, Mink Van Der Molen DR, Young-Afat DA, Batenburg MCT, Van Dam IE, Baas IO, Ernst MF, Maarse W, Sier MF, Schoenmaeckers EJP, Burgmans JPJ, Bijlsma RM, Siesling S, Rakhorst HA, Mureau MA, Van Der Leij F, Doeksen A, Verkooijen HM, UMBRELLA Study Group

doi: 10.1093/jnci/djae310

Lung, Respiratory and Thoracic Cancer

Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland

J Med Econ

Wislez M, Giannopoulou A, Borget I, Lindsay C, Rothschild SI, Vincent B, Milce J, Sultan I, Stollenwerk B, Pless M

doi: 10.1080/13696998.2025.2535225

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Leukemia

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Leuk Lymphoma

Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE

doi: 10.1080/10428194.2025.2495369

Gastrointestinal Cancer

Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial

Lancet Oncol

Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F

doi: 10.1016/S1470-2045(25)00352-3

Related content

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Clinical and patient-reported outcomes after oncoplastic versus conventional breast conserving surgery-a longitudinal, multicenter cohort study

Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY

Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial